{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:14:02Z","timestamp":1778685242927,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HO 2583\/13-1"],"award-info":[{"award-number":["HO 2583\/13-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RI 3503\/3-1"],"award-info":[{"award-number":["RI 3503\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    \u201cAlport spectrum disorder\u201d describes a phenotypically and genotypically multifaceted disease entity encompassing classic autosomal recessive and X-linked Alport syndrome (AS) but also more heterogenous and typically milder, yet not benign, hematuric phenotypes like autosomal dominant AS, formerly also known as thin basement membrane nephropathy (TBMN). Alport spectrum disorder is associated with disease-causing variants in the type IV collagen genes\n                    <jats:italic>COL4A3<\/jats:italic>\n                    ,\n                    <jats:italic>COL4A4<\/jats:italic>\n                    and\n                    <jats:italic>COL4A5<\/jats:italic>\n                    . Variants and genotypes, reported by a genetic diagnostics lab between 2009 and 2014, of 91 index cases with the clinical tentative diagnosis of AS (66\/91), TBMN (21\/91), or AS\/TBMN (not specified further; 4\/91), were reassessed based on 2015 ACMG (American College of Medical Genetics and Genomics) criteria and current amendments. 80 different variants, all originally reported as \u201cmutations\u201d, and their genotypes have been reassessed (\n                    <jats:italic>COL4A3<\/jats:italic>\n                    : 21\/80,\n                    <jats:italic>COL4A4<\/jats:italic>\n                    : 15\/80,\n                    <jats:italic>COL4A5<\/jats:italic>\n                    : 44\/80). In 10\/80 variants, classification changed from disease-causing to variant of uncertain significance (VUS). 69\/91 (76%) index cases included in the analysis could be classified as solved. 22\/91 (24%) index cases had an ambiguous result either on variant, genotype, or both variant and genotype level. VUS cases had a significantly more limited phenotype (e.g., isolated microscopic hematuria) compared to non-downgraded cases (e.g., additional extrarenal manifestations). Reassessment of variants\/genotypes in this study showed a significant reduction in unequivocal genetic diagnoses highlighting variant and genotype interpretation as a dynamic process. Genetic reports of individuals with suspected Alport spectrum disorder, especially those obtained in the pre-ACMG criteria era, should therefore be critically evaluated.\n                  <\/jats:p>","DOI":"10.1038\/s41431-026-02066-1","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T18:26:32Z","timestamp":1773858392000},"page":"630-638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic reassessment of reported variants in individuals with suspicion of Alport spectrum disorder reveals a high rate of ambiguous results"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7503-5801","authenticated-orcid":false,"given":"Korbinian M.","family":"Riedhammer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Richthammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4870-9863","authenticated-orcid":false,"given":"Dominik S.","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmina","family":"\u0106omi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"G\u00fcnthner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias C.","family":"Braunisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja K.","family":"B\u00fcscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanns-Georg","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-7129","authenticated-orcid":false,"given":"Julia","family":"Hoefele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"2066_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.matbio.2018.04.008","volume":"71-72","author":"SD Funk","year":"2018","unstructured":"Funk SD, Lin MH, Miner JH. Alport syndrome and Pierson syndrome: diseases of the glomerular basement membrane. Matrix Biol. 2018;71-72:250\u201361.","journal-title":"Matrix Biol"},{"key":"2066_CR2","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00467-015-3302-4","volume":"31","author":"S Weber","year":"2016","unstructured":"Weber S, Strasser K, Rath S, Kittke A, Beicht S, Alberer M, et al. Identification of 47 novel mutations in patients with Alport syndrome and thin basement membrane nephropathy. Pediatr Nephrol. 2016;31:941\u201355.","journal-title":"Pediatr Nephrol"},{"key":"2066_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/MNH.0000000000000983","volume":"33","author":"P Puapatanakul","year":"2024","unstructured":"Puapatanakul P, Miner JH. Alport syndrome and Alport kidney diseases\u2014elucidating the disease spectrum. Curr Opin Nephrol Hypertens. 2024;33:283\u201390.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2066_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.akdh.2024.02.004","volume":"31","author":"E Chavez","year":"2024","unstructured":"Chavez E, Goncalves S, Rheault MN, Fornoni A. Alport syndrome. Adv Kidney Dis Health. 2024;31:170\u20139.","journal-title":"Adv Kidney Dis Health"},{"key":"2066_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/BF00433075","volume":"364","author":"HJ Rumpelt","year":"1974","unstructured":"Rumpelt HJ, Langer KH, Scharer K, Straub E, Thoenes W. Split and extremely thin glomerular basement membranes in hereditary nephropathy (Alport\u2019s syndrome). Virchows Arch A Pathol Anat Histol. 1974;364:225\u201333.","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"2066_CR6","first-page":"93","volume":"9","author":"GS Spear","year":"1974","unstructured":"Spear GS. Pathology of the kidney in Alport\u2019s syndrome. Pathol Annu. 1974;9:93\u2013138.","journal-title":"Pathol Annu"},{"key":"2066_CR7","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1056\/NEJMra022296","volume":"348","author":"BG Hudson","year":"2003","unstructured":"Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport\u2019s syndrome, Goodpasture\u2019s syndrome, and type IV collagen. N Engl J Med. 2003;348:2543\u201356.","journal-title":"N Engl J Med"},{"key":"2066_CR8","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1046\/j.1523-1755.2003.00234.x","volume":"64","author":"J Savige","year":"2003","unstructured":"Savige J, Rana K, Tonna S, Buzza M, Dagher H, Wang YY. Thin basement membrane nephropathy. Kidney Int. 2003;64:1169\u201378.","journal-title":"Kidney Int"},{"key":"2066_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1681\/ASN.2005070737","volume":"17","author":"K Tryggvason","year":"2006","unstructured":"Tryggvason K, Patrakka J. Thin basement membrane nephropathy. J Am Soc Nephrol. 2006;17:813\u201322.","journal-title":"J Am Soc Nephrol"},{"key":"2066_CR10","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.ekir.2022.06.001","volume":"7","author":"J Savige","year":"2022","unstructured":"Savige J. Heterozygous pathogenic COL4A3 and COL4A4 variants (autosomal dominant Alport syndrome) are common, and not typically associated with end-stage kidney failure, hearing loss, or ocular abnormalities. Kidney Int Rep. 2022;7:1933\u20138.","journal-title":"Kidney Int Rep"},{"key":"2066_CR11","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1097\/01.ASN.0000090034.71205.74","volume":"14","author":"JP Jais","year":"2003","unstructured":"Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a \u201cEuropean Community Alport Syndrome Concerted Action\u201d study. J Am Soc Nephrol. 2003;14:2603\u201310.","journal-title":"J Am Soc Nephrol"},{"key":"2066_CR12","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/ckj\/sfz176","volume":"13","author":"A Matthaiou","year":"2020","unstructured":"Matthaiou A, Poulli T, Deltas C. Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review. Clin Kidney J. 2020;13:1025\u201336.","journal-title":"Clin Kidney J"},{"key":"2066_CR13","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10157-020-01880-1","volume":"24","author":"A Imafuku","year":"2020","unstructured":"Imafuku A, Nozu K, Sawa N, Nakanishi K, Ubara Y. How to resolve confusion in the clinical setting for the diagnosis of heterozygous COL4A3 or COL4A4 gene variants? Discussion and suggestions from nephrologists. Clin Exp Nephrol. 2020;24:651\u20136.","journal-title":"Clin Exp Nephrol"},{"key":"2066_CR14","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.ekir.2018.08.002","volume":"3","author":"J Savige","year":"2018","unstructured":"Savige J. Should we diagnose autosomal dominant alport syndrome when there is a pathogenic heterozygous COL4A3 or COL4A4 variant?. Kidney Int Rep. 2018;3:1239\u201341.","journal-title":"Kidney Int Rep"},{"key":"2066_CR15","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1681\/ASN.2020071065","volume":"32","author":"J Gibson","year":"2021","unstructured":"Gibson J, Fieldhouse R, Chan MMY, Sadeghi-Alavijeh O, Burnett L, Izzi V, et al. Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome. J Am Soc Nephrol. 2021;32:2273\u201390.","journal-title":"J Am Soc Nephrol"},{"key":"2066_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/j.ajkd.2020.03.026","volume":"77","author":"CE Kashtan","year":"2021","unstructured":"Kashtan CE. Alport syndrome: achieving early diagnosis and treatment. Am J Kidney Dis. 2021;77:272\u20139.","journal-title":"Am J Kidney Dis"},{"key":"2066_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.957733","volume":"9","author":"J Comic","year":"2022","unstructured":"Comic J, Riedhammer KM, Gunthner R, Schaaf CW, Richthammer P, Simmendinger H, et al. The multifaceted phenotypic and genotypic spectrum of type-IV-collagen-related nephropathy\u2014a human genetics department experience. Front Med. 2022;9:957733.","journal-title":"Front Med"},{"key":"2066_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"2066_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/GIM.0b013e31816b5cae","volume":"10","author":"CS Richards","year":"2008","unstructured":"Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med. 2008;10:294\u2013300.","journal-title":"Genet Med"},{"key":"2066_CR20","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/humu.23626","volume":"39","author":"AN Abou Tayoun","year":"2018","unstructured":"Abou Tayoun AN, Pesaran T, DiStefano MT, Oza A, Rehm HL, Biesecker LG, et al. Recommendations for interpreting the loss of function PVS1 ACMG\/AMP variant criterion. Hum Mutat. 2018;39:1517\u201324.","journal-title":"Hum Mutat"},{"key":"2066_CR21","unstructured":"Ellard S, Baple EL, Berry I, Forrester N, Turnbull C, Owens M, et al. ACGS Best Practice Guidelines for Variant Classification 2019. https:\/\/www.acgs.uk.com\/media\/11285\/uk-practice-guidelines-for-variant-classification-2019-v1-0-3.pdf."},{"key":"2066_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1300","volume":"8","author":"DS Westphal","year":"2020","unstructured":"Westphal DS, Burkard T, Moscu-Gregor A, Gebauer R, Hessling G, Wolf CM. Reclassification of genetic variants in children with long QT syndrome. Mol Genet Genom Med. 2020;8:e1300.","journal-title":"Mol Genet Genom Med"},{"key":"2066_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ng.2892","volume":"46","author":"M Kircher","year":"2014","unstructured":"Kircher M, Witten DM, Jain P, O\u2019Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310\u20135.","journal-title":"Nat Genet"},{"key":"2066_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248\u20139.","journal-title":"Nat Methods"},{"key":"2066_CR25","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nprot.2009.86","volume":"4","author":"P Kumar","year":"2009","unstructured":"Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073\u201381.","journal-title":"Nat Protoc"},{"key":"2066_CR26","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41431-021-00858-1","volume":"29","author":"J Savige","year":"2021","unstructured":"Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, et al. Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Eur J Hum Genet. 2021;29:1186\u201397.","journal-title":"Eur J Hum Genet"},{"key":"2066_CR27","doi-asserted-by":"crossref","unstructured":"Westphal DS, Pollmann K, Marschall C, Wacker-Gussmann A, Oberhoffer-Fritz R, Laugwitz KL, et al. It is not carved in stone-the need for a genetic reevaluation of variants in pediatric cardiomyopathies. J Cardiovasc Dev Dis. 2022;9:41.","DOI":"10.3390\/jcdd9020041"},{"key":"2066_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/cge.13861","volume":"99","author":"J Boeckhaus","year":"2021","unstructured":"Boeckhaus J, Hoefele J, Riedhammer KM, Tonshoff B, Ehren R, Pape L, et al. Precise variant interpretation, phenotype ascertainment, and genotype-phenotype correlation of children in the EARLY PRO-TECT Alport trial. Clin Genet. 2021;99:143\u201356.","journal-title":"Clin Genet"},{"key":"2066_CR29","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1053\/j.ajkd.2021.02.326","volume":"78","author":"M Furlano","year":"2021","unstructured":"Furlano M, Martinez V, Pybus M, Arce Y, Crespi J, Venegas MDP, et al. Clinical and genetic features of autosomal dominant Alport syndrome: a cohort study. Am J Kidney Dis. 2021;78:560\u201370 e1.","journal-title":"Am J Kidney Dis"},{"key":"2066_CR30","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1681\/ASN.2007040444","volume":"18","author":"K Voskarides","year":"2007","unstructured":"Voskarides K, Damianou L, Neocleous V, Zouvani I, Christodoulidou S, Hadjiconstantinou V, et al. COL4A3\/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am Soc Nephrol. 2007;18:3004\u201316.","journal-title":"J Am Soc Nephrol"},{"key":"2066_CR31","doi-asserted-by":"crossref","unstructured":"Stolpe S, Kowall B, Scholz C, Stang A, Blume C. High Unawareness of Chronic Kidney Disease in Germany. Int J Environ Res Public Health. 2021;18:11752.","DOI":"10.3390\/ijerph182211752"},{"key":"2066_CR32","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","volume":"97","author":"O Gross","year":"2020","unstructured":"Gross O, Tonshoff B, Weber LT, Pape L, Latta K, Fehrenbach H, et al. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport\u2019s syndrome. Kidney Int. 2020;97:1275\u201386.","journal-title":"Kidney Int"},{"key":"2066_CR33","unstructured":"Durkie M, Cassidy EJ, Berry I, Owens M, Turnbull C, Scott RH, et al. ACGS best practice guidelines for variant classification in rare disease 2024. https:\/\/www.acgs.uk.com\/media\/12533\/_media_12533_uk-practice-guidelines-for-variant-classification-v12-2024.pdf. 2024."},{"key":"2066_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97414-0","volume":"11","author":"X Wang","year":"2021","unstructured":"Wang X, Zhang Y, Ding J, Wang F. mRNA analysis identifies deep intronic variants causing Alport syndrome and overcomes the problem of negative results of exome sequencing. Sci Rep. 2021;11:18097.","journal-title":"Sci Rep"},{"key":"2066_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/ndt\/gfae265","volume":"40","author":"R Torra","year":"2025","unstructured":"Torra R, Lipska-Zietkiewicz B, Acke F, Antignac C, Becker JU, Cornec-Le Gall E, et al. Diagnosis, management and treatment of the Alport syndrome\u20142024 guideline on behalf of ERKNet, ERA and ESPN. Nephrol Dial Transpl. 2025;40:1091\u2013106.","journal-title":"Nephrol Dial Transpl"},{"key":"2066_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285\u201391.","journal-title":"Nature"},{"key":"2066_CR37","doi-asserted-by":"crossref","unstructured":"Solanki KV, Hu Y, Moore BS, Abedi V, Avula V, Mirshahi T, et al. The phenotypic spectrum of COL4A3 heterozygotes. Kidney Int Rep. 2023;8:2088\u201399.","DOI":"10.1016\/j.ekir.2023.07.010"},{"key":"2066_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/cge.14471","volume":"105","author":"KM Riedhammer","year":"2024","unstructured":"Riedhammer KM, Simmendinger H, Tasic V, Putnik J, Abazi-Emini N, Stajic N, et al. Is there a dominant-negative effect in individuals with heterozygous disease-causing variants in COL4A3\/COL4A4?. Clin Genet. 2024;105:406\u201314.","journal-title":"Clin Genet"},{"key":"2066_CR39","doi-asserted-by":"crossref","unstructured":"Pagniez MS, Fages V, Gatinois C, Larrue R, Pottier N, Laboux T, et al. Exon location of glycine substitutions impacts kidney survival in autosomal dominant Alport Syndrome. Nephrol Dial Transplant. 2025;40:1522\u20131530.","DOI":"10.1093\/ndt\/gfaf011"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02066-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02066-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02066-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:35:01Z","timestamp":1778682901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02066-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2066"],"URL":"https:\/\/doi.org\/10.1038\/s41431-026-02066-1","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed according to the standards of the Declaration of Helsinki 2013 and approved by the local Ethics Committee of the Technical University of Munich (approval number 521\/16 S). Before inclusion, informed consent of each individual or their legal guardians was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}